Patents by Inventor Søren OTTOSEN

Søren OTTOSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced oligonucleotides for inhibiting RTEL1 expression
    Patent number: 11898145
    Abstract: The present disclosure provides antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1). The disclosure also provides, enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection. Also disclosed are pharmaceutical compositions and their use.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: February 13, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Erik Funder, Natascha Hruschka, Susanne Kammler, Erich Koller, Brian Leonard, Souphalone Luangsay, Susanne Mohr, Tobias Nilsson, Søren Ottosen, Lykke Pedersen, Søren V. Rasmussen, Steffen Schmidt, Sabine Sewing, Daniel Turley, Johanna Marie Walther
  • OLIGOMERS AND OLIGOMER CONJUGATES
    Publication number: 20240035032
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Application
    Filed: February 27, 2023
    Publication date: February 1, 2024
    Applicant: Hoffmann-La roche Inc.
    Inventors: Hassan JAVANBAKH, Søren OTTOSEN, Morten LINDOW
  • OLIGONUCLEOTIDE TREATMENT OF HEPATITIS B PATIENTS
    Publication number: 20230357773
    Abstract: The present invention provides oligonucleotides for use in the treatment of hepatitis B or hepatitis B virus infection in a human patient.
    Type: Application
    Filed: February 3, 2023
    Publication date: November 9, 2023
    Inventors: Søren OTTOSEN, Henrik MUELLER, Hardean ACHNECK, Douglas M. FAMBROUGH, Bob Dale BROWN
  • PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBV
    Publication number: 20230123601
    Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of certain antiviral compounds and immune modulator compounds.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 20, 2023
    Inventors: Søren OTTOSEN, Henrik MUELLER
  • PHARMACEUTICAL COMBINATION OF A THERAPEUTIC OLIGONUCLEOTIDE TARGETING HBV AND A TLR7 AGONIST FOR TREATMENT OF HBV
    Publication number: 20230119360
    Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a therapeutic oligonucleotide targeting HBV and a TLR7 agonist for use in the treatment of a chronic hepatitis B patient.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 20, 2023
    Inventors: Lu GAO, Yonghong ZHU, Søren OTTOSEN, Henrik MUELLER, Xue ZHOU, Julie Elisabeth Françoise BLAISING, Yuyan JIN, Qingyan BO, Gaurav TYAGI
  • Oligomers and oligomer conjugates
    Patent number: 11591598
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: February 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hassan Javanbakh, Søren Ottosen, Morten Lindow
  • Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
    Patent number: 11534452
    Abstract: A method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection is provided, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. Inhibitors of PAPD5 or PAPD7 are provided for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: December 27, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Hassan Javanbakht, Søren Ottosen, Lykke Pedersen, Henrik Mueller
  • Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
    Patent number: 11484546
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: November 1, 2022
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • Oligonucleotides for reduction of PD-L1 expression
    Patent number: 11466081
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: October 11, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION
    Publication number: 20220251556
    Abstract: Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described.
    Type: Application
    Filed: February 1, 2022
    Publication date: August 11, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Erik FUNDER, Natascha HRUSCHKA, Susanne KAMMLER, Erich KOLLER, Brian LEONARD, Souphalone LUANGSAY, Susanne MOHR, Tobias NILSSON, Søren OTTOSEN, Lykke PEDERSEN, Søren V. RASMUSSEN, Steffen SCHMIDT, Sabine SEWING, Daniel TURLEY, Johanna Marie WALTHER
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20220042022
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 10, 2022
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION
    Publication number: 20220031730
    Abstract: The present invention relates to enhanced antisense oligonucleotides that are complementary to the Far Upstream Element-Binding Protein 1 (FUBP1) and are capable of reducing a FUBP1 target nucleic acid, such as FUBP1 mRNA. The invention relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of the enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for destabilizing cccDNA, such as HBV cccDNA. The invention further relates to enhanced antisense oligonucleotides targeting FUBP1 or conjugates thereof for use in treating cancer. A pharmaceutical composition and its use in the treatment and/or prevention of an HBV infection, or its use in the treatment of cancer is also disclosed.
    Type: Application
    Filed: June 25, 2021
    Publication date: February 3, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sabine SEWING, Søren OTTOSEN, Jacob RAVN, Lykke PEDERSEN, Souphalone LUANGSAY, Erich KOLLER, Johanna Marie WALTHER, Helene Maria GYLLING, Natascha HRUSCHKA, Susanne MOHR, Valentina D'ARIENZO
  • OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION
    Publication number: 20210147535
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Application
    Filed: August 21, 2020
    Publication date: May 20, 2021
    Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
  • Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
    Patent number: 10953034
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 23, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • OLIGOMERS AND OLIGOMER CONJUGATES
    Publication number: 20210054381
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Application
    Filed: September 4, 2020
    Publication date: February 25, 2021
    Applicant: Hoffmann-La roche Inc.
    Inventors: Hassan JAVANBAKH, Søren OTTOSEN, Morten LINDOW
  • Oligonucleotides for reduction of PD-L1 expression
    Patent number: 10829555
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: November 10, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • Oligomers and oligomer conjugates
    Patent number: 10767181
    Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: September 8, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hassan Javanbakh, Søren Ottosen, Morten Lindow
  • Oligonucleotides for reduction of PD-L1 expression
    Patent number: 10745480
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 18, 2020
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION
    Publication number: 20200247884
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Application
    Filed: April 2, 2020
    Publication date: August 6, 2020
    Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20200157546
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: October 28, 2019
    Publication date: May 21, 2020
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann